Carbamazepine for schizophrenia (Q24244150)

Cochrane Database of Systematic Reviews

Europe PubMed Central

title

Carbamazepine for schizophrenia (English)

0 references

0 references

0 references

2

0 references

Stefan Leucht

series ordinal

1

0 references

John J. McGrath

series ordinal

3

object named as

John McGrath

0 references

author name string

Paul White

series ordinal

4

0 references

publication date

18 July 2007

0 references

published in

0 references

cites work

Carbamazepine maintenance treatment in outpatient schizophrenics

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258.PUB2

A double-blind trial of carbamazepine in negative symptom schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258.PUB2

Carbamazepine in the psychiatric patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258.PUB2

Weight gain with clozapine compared to first generation antipsychotic medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258.PUB2

Pediatric psychopharmacotherapy: a review of recent research

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258.PUB2

Carbamazepine in treatment of violent schizophrenics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258.PUB2

Exacerbation of psychosis after discontinuation of carbamazepine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258.PUB2

Efficacy of adjunctive carbamazepine in the treatment of chronic schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258.PUB2

Adjunctive treatments in schizophrenia: pharmacotherapies and electroconvulsive therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258.PUB2

A review of schizoaffective disorder: II. Somatic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258.PUB2

Carbamazepine for the violent psychiatric patient.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258.PUB2

Treatment of the neuroleptic-nonresponsive schizophrenic patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258.PUB2

Chronic toxicologic evaluation of hydroxyphenamate and possible synergism with phenothiazines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258.PUB2

Review: treatment of schizophrenia. State of the art.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258.PUB2

A Comparison of Carbamazepine Divitabs and a Normal Carbamazepine Preparation in Psychiatric and Oligophrenic Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258.PUB2

A double-blind study of adjunctive carbamazepine versus placebo on excited states of schizophrenic and schizoaffective disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258.PUB2

Clinical efficacy of carbamazepine in affective, schizoaffective, and schizophrenic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258.PUB2

Treatment of inhalant-induced psychotic disorder with carbamazepine versus haloperidol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258.PUB2

Drug strategies and treatment-resistant schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258.PUB2

Effect of switching carbamazepine to oxcarbazepine on the plasma levels of neuroleptics. A case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258.PUB2

Serum homovanillic acid concentrations in carbamazepine-treated chronic schizophrenics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258.PUB2

Open clinical trial of carbamazepine in chronic schizophrenic inpatients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258.PUB2

Negative symptoms in schizophrenia. Definition and reliability

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258.PUB2

Improving the quality of reporting of randomized controlled trials. The CONSORT statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258.PUB2

Statistics notes. Trials randomised in clusters

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258.PUB2

When Symptoms Persist: Choosing Among Alternative Somatic Treatments for Schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258.PUB2

Meta-analysis. Unresolved issues and future developments

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258.PUB2

The unit of analysis error in studies about physicians' patient care behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258.PUB2

Issues in the meta-analysis of cluster randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258.PUB2

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258.PUB2

Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258.PUB2

A rating scale for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258.PUB2

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258.PUB2

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258.PUB2

The positive and negative syndrome scale (PANSS) for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258.PUB2

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258.PUB2

Electroconvulsive therapy for schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258.PUB2

Carbamazepine-induced changes in plasma levels of neuroleptics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258.PUB2

Carbamazepine for withdrawal pseudohallucinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258.PUB2

Fatal agranulocytosis in a chronic schizophrenic patient treated with carbamazepine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258.PUB2

Carbamazepine and haloperidol v placebo and haloperidol in excited psychoses. A controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258.PUB2

7 January 2021

Lithium vs carbamazepine in the maintenance treatment of schizoaffective disorder: a randomised study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258.PUB2

7 January 2021

Interaction between carbamazepine and bromperidol

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258.PUB2

7 January 2021

Carbamazepine-induced reduction of blood levels of haloperidol in chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258.PUB2

7 January 2021

Carbamazepine as an adjunct of antipsychotic therapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258.PUB2

7 January 2021

Doubleblind evaluation of the antimanic properties of carbamazepine as a comedication to haloperidol

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258.PUB2

7 January 2021

Acute psychosis with carbamazepine and sodium valproate.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258.PUB2

7 January 2021

Evidence of ten psychotic syndromes.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258.PUB2

7 January 2021

The drug-drug interaction effects of haloperidol on plasma carbamazepine levels

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258.PUB2

7 January 2021

Significantly higher plasma haloperidol level during cotreatment with carbamazepine may herald cardiac change.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258.PUB2

7 January 2021

Inpatient clinical trial of lorazepam for the management of manic agitation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258.PUB2

7 January 2021

Change in haloperidol level due to carbamazepine--a complicating factor in combined medication for schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258.PUB2

7 January 2021

Effects of carbamazepine and valproate on haloperidol plasma levels and on psychopathologic outcome in schizophrenic patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258.PUB2

7 January 2021

Pharmacological treatment strategies in the non-responsive schizophrenic patient

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258.PUB2

7 January 2021

Carbamazepine adjunct for nonresponsive psychosis with prior hallucinogenic abuse

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258.PUB2

7 January 2021

Carbamazepine for atypical psychosis with episodic hostility.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258.PUB2

7 January 2021

Response of functional hallucinations to carbamazepine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258.PUB2

7 January 2021

Does carbamazepine-induced reduction of plasma haloperidol levels worsen psychotic symptoms?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258.PUB2

7 January 2021

Carbamazepine in the treatment of catatonia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258.PUB2

7 January 2021

A carbamazepine trial in chronic, treatment-refractory schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258.PUB2

7 January 2021

Mood disorders in the psychoneurologic borderland: three cases of responsiveness to carbamazepine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258.PUB2

7 January 2021

Use of carbamazepine in acute psychosis: a controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258.PUB2

7 January 2021

Carbamazepine in the treatment of aggressive behavior in schizophrenic patients: a case report

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258.PUB2

7 January 2021

Adjunctive carbamazepine or lithium carbonate in therapy-resistant chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258.PUB2

7 January 2021

An open clinical trial of carbamazepine in treatment-resistant bipolar and schizo-affective psychotics

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258.PUB2

7 January 2021

Comparison of carbamazepine and lithium in the prophylaxis of bipolar disorders. A meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258.PUB2

7 January 2021

Carbamazepine augmentation for schizophrenia: how good is the evidence?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001258.PUB2

7 January 2021

10.1002/14651858.CD001258.PUB2

Identifiers

DOI

0 references

Fatcat ID

release_lgz3rwnj5zdhnibxaukjnoytrq

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/lgz3rwnj5zdhnibxaukjnoytrq

24 November 2022